HCPCS Level II code J0221 specifies a 10 mg unit of alglucosidase alfa (Lumizyme), an enzyme replacement therapy administered by injection or infusion for Pompe disease. This biologic drug code is nationally relevant due to high per-dose cost, specialized administration needs, and implications for coverage policies and care coordination for rare disease patients.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and typical sites of care, coverage and prior authorization practices among major payers, and billing benchmarks where available. The publication addresses common billing considerations for a high-cost infused biologic, including unit-based coding and implications for service lines that manage infusion therapies.

The report highlights what providers and administrators need to know about reimbursement framing, payer-specific coverage patterns, and operational considerations for delivering alglucosidase alfa. Benchmarks, policy updates, and coding notes are summarized to support administrative planning and claims submission accuracy. Data not available in the input is noted where applicable.